- Home
- MYGN vs XYF Comparison
MYGN vs XYF Comparison
Compare MYGN & XYF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MYGN | XYF |
|---|---|---|
| Founded | 1991 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 625.5M | 260.6M |
| IPO Year | 1995 | 2018 |
Fundamental Metrics
Financial Performance| Metric | MYGN | XYF |
|---|---|---|
| Price | $7.09 | $6.98 |
| Analyst Decision | Hold | |
| Analyst Count | 13 | 0 |
| Target Price | ★ $12.58 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 253.1K |
| Earning Date | 11-03-2025 | 11-20-2025 |
| Dividend Yield | N/A | ★ 8.03% |
| EPS Growth | N/A | ★ 49.84 |
| EPS | N/A | ★ 5.72 |
| Revenue | $825,300,000.00 | ★ $1,106,908,607.00 |
| Revenue This Year | $0.10 | N/A |
| Revenue Next Year | $5.28 | N/A |
| P/E Ratio | ★ N/A | $1.22 |
| Revenue Growth | 0.21 | ★ 47.14 |
| 52 Week Low | $3.76 | $6.47 |
| 52 Week High | $16.63 | $20.36 |
Technical Indicators
Market Signals| Indicator | MYGN | XYF |
|---|---|---|
| Relative Strength Index (RSI) | 47.96 | 21.54 |
| Support Level | $6.93 | $6.47 |
| Resistance Level | $7.38 | $12.57 |
| Average True Range (ATR) | 0.39 | 0.63 |
| MACD | 0.03 | -0.10 |
| Stochastic Oscillator | 39.88 | 9.47 |
Price Performance
Historical ComparisonAbout MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About XYF X Financial each representing six
X Financial is a Cayman Islands-based technology-driven personal finance company. Along with its subsidiaries, the firm provides diversified investment opportunities to investors in China through its wealth management platform, Xiaoying Wealth Management. Loan products offered by the company include Xiaoying Card Loan, Xiaoying Preferred Loan, and Xiaoying Housing Loan. The company generates revenue from loan facilitation service, post-origination service, and guarantee services provided.